JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

Corvus Pharmaceuticals Inc

Fermé

4.28 -0.7

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.18

Max

4.34

Chiffres clés

By Trading Economics

Revenu

27M

15M

Employés

31

EBITDA

-1.8M

-9.9M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+201.62% upside

Dividendes

By Dow Jones

Prochains Résultats

7 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

82M

359M

Ouverture précédente

4.98

Clôture précédente

4.28

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 août 2025, 23:11 UTC

Résultats

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 août 2025, 22:45 UTC

Résultats

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 août 2025, 22:39 UTC

Résultats

Great-West Lifeco Logs Lower 2Q Profit

5 août 2025, 21:32 UTC

Résultats

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 août 2025, 00:00 UTC

Acquisitions, Fusions, Rachats

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 août 2025, 00:00 UTC

Acquisitions, Fusions, Rachats

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 août 2025, 00:00 UTC

Acquisitions, Fusions, Rachats

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 août 2025, 00:00 UTC

Acquisitions, Fusions, Rachats

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 août 2025, 23:48 UTC

Market Talk

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 août 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 août 2025, 23:19 UTC

Market Talk

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 août 2025, 23:03 UTC

Market Talk
Résultats

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 août 2025, 22:22 UTC

Résultats

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 août 2025, 22:21 UTC

Résultats

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 août 2025, 22:20 UTC

Résultats

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 août 2025, 22:18 UTC

Résultats

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 août 2025, 22:17 UTC

Résultats

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 août 2025, 22:17 UTC

Résultats

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 août 2025, 22:16 UTC

Résultats

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 août 2025, 22:16 UTC

Résultats

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 août 2025, 22:15 UTC

Résultats

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 août 2025, 22:13 UTC

Résultats

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 août 2025, 22:13 UTC

Résultats

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 août 2025, 22:12 UTC

Résultats

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 août 2025, 22:12 UTC

Résultats

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 août 2025, 21:58 UTC

Résultats

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 août 2025, 21:30 UTC

Résultats

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 août 2025, 21:26 UTC

Résultats

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 août 2025, 21:23 UTC

Résultats

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 août 2025, 21:17 UTC

Résultats

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

201.62% hausse

Prévisions sur 12 Mois

Moyen 13 USD  201.62%

Haut 17 USD

Bas 11 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

4

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

3.165 / 3.5827Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.